CA2292415A1 - Molecules de liaison avec b7 destinees au traitement d'affections immunitaires - Google Patents

Molecules de liaison avec b7 destinees au traitement d'affections immunitaires Download PDF

Info

Publication number
CA2292415A1
CA2292415A1 CA002292415A CA2292415A CA2292415A1 CA 2292415 A1 CA2292415 A1 CA 2292415A1 CA 002292415 A CA002292415 A CA 002292415A CA 2292415 A CA2292415 A CA 2292415A CA 2292415 A1 CA2292415 A1 CA 2292415A1
Authority
CA
Canada
Prior art keywords
cells
antibody
antibodies
mab
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002292415A
Other languages
English (en)
Inventor
Katrien Lorre
Erwin Sablon
Marie-Ange Buyse
Alfons Bosman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2292415A1 publication Critical patent/CA2292415A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA002292415A 1997-06-20 1998-06-22 Molecules de liaison avec b7 destinees au traitement d'affections immunitaires Abandoned CA2292415A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97870092.0 1997-06-20
EP97870092 1997-06-20
PCT/EP1998/003791 WO1998058965A2 (fr) 1997-06-20 1998-06-22 Molecules de liaison avec b7 destinees au traitement d'affections immunitaires

Publications (1)

Publication Number Publication Date
CA2292415A1 true CA2292415A1 (fr) 1998-12-30

Family

ID=8231013

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002292415A Abandoned CA2292415A1 (fr) 1997-06-20 1998-06-22 Molecules de liaison avec b7 destinees au traitement d'affections immunitaires

Country Status (4)

Country Link
EP (1) EP0988321A2 (fr)
AU (1) AU8800598A (fr)
CA (1) CA2292415A1 (fr)
WO (1) WO1998058965A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001243617A1 (en) * 2000-03-14 2001-09-24 Arch Development Corporation Use of a combination of agents that modulate b7 activity in inhibiting intestinal allograft rejection
AU2001249182A1 (en) * 2000-03-14 2001-09-24 Genetics Institute Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
AU2001247401A1 (en) * 2000-03-14 2001-09-24 Genetics Institute Inc. Therapies that improve graft survival, using antibodies against a b7 antigen
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
US20030031675A1 (en) * 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
WO2003014293A2 (fr) * 2001-08-02 2003-02-20 Eli Lilly And Company Nouveaux analogues de polypeptides et proteines hybrides et leurs procedes d'utilisation
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EA012622B1 (ru) 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
RU2401842C2 (ru) 2004-10-08 2010-10-20 Домантис Лимитед Антагонисты и способы их применения
CN101128487B (zh) 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
PE20110385A1 (es) 2008-07-18 2011-06-22 Bristol Myers Squibb Co Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4
US9493564B2 (en) 2008-10-02 2016-11-15 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
WO2014120916A1 (fr) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Anticorps à domaines pegylés monovalents pour la liaison à cd28 et leurs méthodes d'utilisation
JP6776254B2 (ja) * 2015-03-16 2020-10-28 イッサム、リサーチ、デベロップメント、カンパニー、オブ、ザ、ヘブライ、ユニバーシティー、オブ、イエルサレム、リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． Ｂ７リガンド二量体界面に由来する単離されたペプチドおよびそれらの使用
TW201722985A (zh) 2015-11-02 2017-07-01 戊瑞治療有限公司 Cd80胞外域多肽及其用於癌症治療
MX2019012849A (es) 2017-04-28 2019-11-28 Five Prime Therapeutics Inc Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
CN110305220B (zh) * 2018-03-27 2022-10-11 孙嘉琳 一种癌靶向增强型抗肿瘤融合蛋白及制备方法及用途
CN110305221B (zh) * 2018-03-27 2022-10-11 孙嘉琳 一种增强型抗肿瘤融合蛋白及制备方法及用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
WO1996014865A1 (fr) * 1994-11-10 1996-05-23 Repligen Corporation Procedes d'inhibition de la reaction du greffon contre l'hote lors d'une greffe de moelle osseuse
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DE69731836T2 (de) * 1996-07-23 2005-12-01 Pangenetics B.V. Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann

Also Published As

Publication number Publication date
AU8800598A (en) 1999-01-04
EP0988321A2 (fr) 2000-03-29
WO1998058965A3 (fr) 1999-05-14
WO1998058965A2 (fr) 1998-12-30

Similar Documents

Publication Publication Date Title
CA2292415A1 (fr) Molecules de liaison avec b7 destinees au traitement d'affections immunitaires
AU748587B2 (en) Methods and compositions for immunomodulation
JP6663653B2 (ja) ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途
US7459544B2 (en) Nucleic acids encoding B7-2 fusion proteins
JP4467188B2 (ja) 多重特異的結合分子とその使用
US6974863B2 (en) Antibody for 4-1BB
JP4327350B2 (ja) エピトープへの結合能力を保持する結合部位ドメインの同定のための新規方法
AU694926B2 (en) Humanised antibodies
US8187598B2 (en) Methods of treating cancer by administering antibodies to CD200
JPH08511420A (ja) 抗 体
JPH09202800A (ja) Ｃｔｌａ４変異体分子およびそれの使用
JP2000504564A (ja) 修飾エフェクター機能を有する免疫グロブリン融合タンパク質および抗体並びにこれらの使用
JPH09509826A (ja) 活性化ｃｄ４▲上＋▼ｔ細胞の表層上のレセプターに対するリガンド（ａｃｔ−４−ｌ）
NO316223B1 (no) Blanding omfattende et B7-bindende molekyl og et IL4-bindende molekyl, samtanvendelse derav
JP2009060905A (ja) Ｂ７−２：ｃｔｌａ４／ｃｄ２８カウンターレセプター
JPH08149981A (ja) Ｔ細胞α鎖による抗原特異的免疫制御の方法
CN117264062A (zh) 一种特异性结合Trop2的抗体或其抗原结合片段及其制备方法和应用
WO1997035004A1 (fr) Stimulation cellulaire
US20060063923A1 (en) 4-1BB peptides and methods for use
AU2004200586C1 (en) Novel CTLA4/CD28 ligands and uses therefor
AU2006203123A1 (en) Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells

Legal Events

Date Code Title Description
FZDE Discontinued